Dermagraft® is an FDA-approved, bioengineered human dermal substitute indicated for the healing of diabetic foot ulcers (DFUs).1
Dermagraft helps restore the compromised wound bed and heal DFUs by providing metabolically active fibroblasts seeded on a bioabsorbable scaffold that produce many of the same proteins and growth factors that support the healing response in healthy skin: human collagen, extracellular matrix (ECM) proteins, and cytokines and growth factors.2,3,4 Through extensive research, Dermagraft has been proven to close more DFUs, faster both in clinical and real world settings.5,6,7
For more information on Dermagraft please visit www.dermagraft.com.
- Dermagraft Directions for Use. Organogenesis. 2013.
- Roberts C, Mansbridge J. The scientific basis and differentiating features of Dermagraft. Can J Plast Surg. 2002;10(Suppl A):6A-13A.
- Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. Adv Skin Wound Care. 2000;13(suppl 2):6-11.
- Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366:1736-1743.
- Marston WA et al. Diabetes Care. 2003;26(6):1701-1705.
- Frykberg R et al. Adv Skin Wound Care. 2015;28(1):17-20.
- Kirsner RS et al. Poster presented at: the Symposium on Advanced Wound Care; October 17, 2014; Las Vegas, N.